22 May 2013
Keywords: oxford, biomedica, licenses, tech, merck, uk-based, signed
Article | 16 February 2004
UK-based Oxford BioMedica has signed a license agreement for its LentiVector technology with US drug major Merck & Co.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 February 2004
23 February 2004
© 2013 thepharmaletter.com